Clinical Trials Logo

Drug-Induced Nephropathy clinical trials

View clinical trials related to Drug-Induced Nephropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06122311 Recruiting - Clinical trials for Drug-Induced Nephropathy

Drug Nephrotoxicity Amelioration by N-acetylcysteine

Start date: July 16, 2023
Phase: N/A
Study type: Interventional

When treating individuals with febrile neutropenia, amphotericin B (AmB-d) is one of the most effective treatments against often fatal systemic fungal infections.Nephrotoxicity from amphotericin B can develop with an incidence of up to 80.This emphasizes the value of nephroprotectant agent use.Because of N-acetylcysteine's antioxidant, antiapoptotic, vasodilator properties and its therapeutic effects on contrast nephropathy. Acetylcysteine's impact on amphotericin B-induced nephrotoxicity in cancer patients is assessed.

NCT ID: NCT05851222 Not yet recruiting - Acute Kidney Injury Clinical Trials

A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs (NeoAKI STOP)

NeoAKISTOP
Start date: August 1, 2023
Phase:
Study type: Observational

This observational retrospective study aims to learn about the incidence of acute kidney (AKI) injury in newborns in infants exposed to nephrotoxic drugs with a big data approach. The main question it aims to answer are: - Develop a model that can predict the occurrence of AKI in infants admitted to the NICU; - Identify the drug or combination of drugs associated with an increased risk of AKI. The group of infants exposed to drugs will be defined based on exposure for at least 1-day tone one or more therapies commonly used in the NICU. Once the AKI event has occurred, the observation of the trend of daily creatinine and diuresis values will be continued for the period covered by the study.

NCT ID: NCT05613361 Recruiting - Acute Kidney Injury Clinical Trials

The Effect of Curcumin Against Colistin-induced Nephrotoxicity

Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this study is to investigate the possible nephroprotective effect of curcumin in critically ill patients receiving colistin.

NCT ID: NCT02882373 Withdrawn - Hypertension Clinical Trials

Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury

Start date: October 23, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well arginine works in treating patients with kidney injury caused by anti-VEGF drugs used in standard treatment for cancer. Arginine is a nutritional supplement that may control side effects of anti-cancer drugs such as high blood pressure and protein in the urine and may also help to improve kidney function in patients.